Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

IV Insulin Therapy Developer Defends Diabetes Treatment Before CMS

This article was originally published in The Gray Sheet

Executive Summary

CMS should evaluate individually the various techniques it categorizes as outpatient intravenous insulin therapy before deciding which, if any, it will cover, say two commenters to the Medicare agency

You may also be interested in...



Outpatient IV Insulin Therapy Evidence Doesn't Warrant Coverage, CMS Says

Evidence supporting outpatient intravenous insulin therapy as an adjunctive diabetes treatment is insufficient to justify Medicare coverage, CMS says in a Sept. 25 proposed decision memo

CMS Exploring Coverage Of Outpatient Intravenous Insulin Treatments

Outpatient intravenous insulin treatment could gain traction as an adjunctive diabetes therapy under a CMS coverage analysis initiated March 25

Chloroquine ‘Approval’ For COVID-19 And The US FDA’s New Reality

Asking whether FDA’s decision to allow emergency use of two old anti-malarial drugs was ‘political’ misses the point. The issue already was political, and FDA’s action may well be the best way to keep some measure of federal control on supplies of a drug with important other uses.

Topics

UsernamePublicRestriction

Register

MT028115

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel